Myoepithelial Cells May Be Key to Suppression of DCIS Growth

Oncology NEWS InternationalOncology NEWS International Vol 6 No 4
Volume 6
Issue 4

LOS ANGELES--Laboratory studies from the UCLA School of Medicine point to a role for myoepithelial cells in suppressing breast cancer invasion, said researcher Mark Sternlicht, PhD. Myo-epithelial cells lie between the epithelium and the basement membrane. They synthesize and maintain the basement membrane and can promote epithelial differentiation. They are found surrounding benign and nonmalignant lesions.

LOS ANGELES--Laboratory studies from the UCLA School of Medicine pointto a role for myoepithelial cells in suppressing breast cancer invasion,said researcher Mark Sternlicht, PhD. Myo-epithelial cells lie betweenthe epithelium and the basement membrane. They synthesize and maintainthe basement membrane and can promote epithelial differentiation. Theyare found surrounding benign and nonmalignant lesions.

"Myoepithelial cells rarely transform," Dr. Sternlicht saidat the San Antonio Breast Cancer Symposium. "And when they do, theytransform to benignity or low-grade neoplasms that do not invade and donot metastasize."

Surrogates Developed

Researchers at the UCLA laboratory, under the direction of Dr. SanfordBarsky, have developed cell lines and transplantable xenografts from benignmyoepithe-lial tumors to serve as a surrogate to study the effects of myoepithelialcells on breast cancer invasion.

"These myoepithelial tumors are slow growing; it takes six monthsof nude mouse growth to reach about 1.5 cm in diameter," Dr. Sternlichtsaid. He noted that these tumors make an abundant extracellular matrix,composed of a number of basement membrane and non-basement membrane molecules.

More importantly, he said, myoepithe-lial cells express high levelsof proteinase inhibitors and angiogenic inhibitors, and very low levelsof proteinase and no angiogenic-stimulating factors. Many of these proteinaseand angiogenic inhibitors can be seen selectively in tissue sections ofductal carcinoma in situ (DCIS) in the surrounding myoepithelial layer.

One of the myoepithelial cell lines, HMS1, has been shown in vitro todramatically inhibit tumor invasion and angiogenesis (endothelial cellmigration and mitogenesis). The UCLA work further suggests that the anti-invasiveeffect is mediated in part through maspin, a member of the serpin superfamilyof proteinase inhibitors, while the angiogenic inhibition is mediated primarilythrough thrombospondin-1.

With all of this evidence for the "myoepithelial defense,"Dr. Sternlicht hypothesizes that DCIS is regulated by the paracrine interactionof the myoepi-thelial cells and "this is why DCIS stays confined forso many years and why there is no demonstrable genetic alteration betweenDCIS and invasive cancer."

Related Videos
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
The randomized, placebo-controlled, double-blind phase 3 CALLA trial assessed the combination of durvalumab and chemoradiotherapy vs placebo and chemoradiotherapy.
Findings from the phase 3 CALLA trial indicated that intensity modulated radiation therapy was administered in 88.1% of patients with high-risk locally advanced cervical cancer treated with durvalumab and chemoradiotherapy vs 88.1% with placebo and chemoradiotherapy.
Jyoti S. Mayadev, MD, indicated that durvalumab (Imfinzi) plus chemotherapy resulted in low rates of high-grade late-onset toxicities in the phase 3 CALLA trial, which may be due in part to the quality of the technology employed during the study.
Jyoti S. Mayadev, MD, indicated that future research for cervical cancer will be focused on combination immune checkpoint inhibitors and biomarker research.
Durvalumab appeared to have no impact on the ability to deliver safe and timely radiation therapy to patients with high-risk locally advanced cervical cancer, according to Jyoti S. Mayadev, MD.
The 12-month progression-free survival rates among patients with high-risk locally advanced cervical cancer were comparable with durvalumab plus chemoradiotherapy vs placebo plus radiotherapy.
Cervical Cancer
woman speaking with physician
Related Content